Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Pelthos Therapeutics Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2023
FY2024
FY2025
Revenue
0
16.8
Cost of revenue
0
3.99
Gross profit
0
12.8
Research and development
0.39
2.58
1.18
1.23
Selling, general and administrative
6.39
42.5
General and administrative
1.1
2.74
4.11
Operating expenses
2.32
6.86
7.57
Operating income
-2.32
-6.86
-7.57
-32.4
Interest expense
0.14
0.31
0.79
3.01
Other non-operating income
-0.14
-0.52
-0.38
-18.3
Pre-tax income
-2.46
-7.38
-7.96
-50.7
Income tax
0
-7.39
Net income
-2.46
-7.38
-7.96
-43.3
EBITDA
-7.57
-31.7
EPS, basic
56.38
-57.68
-14.27
-23.04
EPS, diluted
56.38
-57.68
-14.27
-23.04
Shares, basic (weighted)
0.04
0.13
0.56
1.88
Shares, diluted (weighted)
0.04
0.13
0.56
1.88
Balance sheet
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
0.1
0.1
0.51
18
Receivables
0
8.86
Inventory
0
23.6
Other current assets
0.11
2.96
Total current assets
0.06
0.1
1.37
53.4
Property, plant and equipment
0
9.59
Lease right-of-use assets
0
3.25
Goodwill
0
24.7
Intangible assets
0
39.5
Total assets
0.06
0.1
1.37
130
Accounts payable
2.99
4.62
1.9
2.99
Accrued liabilities
0.22
0.65
0
15.4
Deferred revenue
0
0.97
Total current liabilities
3.76
6.54
4.08
26
Lease liabilities
0
2.75
Other non-current liabilities
0
30.1
Total liabilities
3.76
6.54
4.08
91.5
Paid-in capital
2.43
7.07
18.8
104
Retained earnings
-6.14
-13.5
-21.5
-64.8
Other comprehensive income
0
Shareholders' equity
-3.71
-6.45
-2.71
38.9
Total equity
-3.71
-6.45
-2.71
38.9
Total liabilities and equity
0.06
0.1
1.37
130
Shares outstanding
0.11
0.39
0.61
3.23
Cash flow statement
FY2023
FY2023
FY2024
FY2025
Net income
-2.46
-7.38
-7.96
-43.3
Depreciation and amortization
0
0.73
Stock-based compensation
0.11
1.73
1.8
5.46
Deferred income tax
0
-7.39
Change in receivables
0
-8.81
Change in inventory
0
1.78
Change in payables
0.41
1.63
1.18
1.36
Cash from operations
-1.57
-0.98
-5.79
-22.6
Capital expenditures
0
-0.1
Cash from investing
0
-5.24
Debt repaid
-0.22
-0.85
Stock issued
0.26
5.97
0
Share buybacks
-0.08
0
Cash from financing
1.62
1.02
6.21
45.3
Net change in cash
0.06
0.04
0.42
17.5
Free cash flow
-5.79
-22.7
Interest paid
0
0.02
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $22.19 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
78.6%
Gross profit / revenue.
Operating margin
-133.4%
Operating income / revenue.
Pre-tax margin
-216.6%
Pre-tax income / revenue.
Net margin
-199.5%
Net income / revenue.
Operating cash flow margin
-97.7%
Cash from operations / revenue.
Return on assets (ROA)
-62.9%
Net income / average total assets.
R&D / revenue
3.0%
Research and development expense / revenue.
SG&A / revenue
200.6%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
21.3%
Stock-based compensation (from the cash flow statement) / revenue.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
9,425.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
1,233.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
237.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
250.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.98x
Current assets / current liabilities.
Quick ratio
1.21x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.76x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$24.41
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$12.23
Revenue / diluted weighted shares.
Operating cash flow per share
-$11.95
Cash from operations / diluted weighted shares.
Book value per share
-$0.40
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.96x
Market cap / revenue.
EV/Sales
1.40x
Enterprise value / revenue.
Earnings yield
-101.7%
Net income / market cap (the inverse of P/E).
What was Pelthos Therapeutics Inc.'s revenue in fiscal 2025?
Pelthos Therapeutics Inc. reported revenue of $16.8M for fiscal 2025.
Was Pelthos Therapeutics Inc. profitable in fiscal 2025?
No. It reported a net loss of $43.3M.
How much free cash flow did Pelthos Therapeutics Inc. generate in fiscal 2025?
Cash from operations of $22.6M minus capital expenditures of $99.0K left free cash flow of -$22.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.